Lappe Mark has filed 15 insider transactions across 1 company since May 2024.
Most recent transaction: a purchase of 26963 shares of Inhibrx Biosciences, Inc. ($INBX) on September 12, 2024.
Activity breakdown: 11 open-market purchases and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sept. 12, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | P | Common Stock | 26963 | $15.05 | 912,376.0000 | 14,476,000 | 3.05% | 0.19% |
| Sept. 16, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | P | Common Stock | 13037 | $17.13 | 925,413.0000 | 14,476,000 | 1.43% | 0.09% |
| Sept. 6, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | P | Common Stock | 26000 | $15.29 | 867,413.0000 | 14,476,000 | 3.09% | 0.18% |
| Sept. 9, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | P | Common Stock | 9500 | $15.21 | 876,913.0000 | 14,476,000 | 1.10% | 0.07% |
| Sept. 10, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | P | Common Stock | 8500 | $15.19 | 885,413.0000 | 14,476,000 | 0.97% | 0.06% |
| Aug. 29, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | P | Common Stock | 10000 | $14.03 | 811,413.0000 | 14,476,000 | 1.25% | 0.07% |
| Aug. 30, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | P | Common Stock | 10000 | $14.02 | 821,413.0000 | 14,476,000 | 1.23% | 0.07% |
| Sept. 3, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | P | Common Stock | 15288 | $15.66 | 836,701.0000 | 14,476,000 | 1.86% | 0.11% |
| Sept. 3, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | P | Common Stock | 4712 | $16.31 | 841,413.0000 | 14,476,000 | 0.56% | 0.03% |
| Aug. 20, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | P | Common Stock | 27055 | $12.97 | 788,468.0000 | 14,476,000 | 3.55% | 0.19% |
| Aug. 21, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | P | Common Stock | 12945 | $12.93 | 801,413.0000 | 14,476,000 | 1.64% | 0.09% |
| May 29, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | A | Common Stock | 621548 | $0.00 | 761,413.0000 | 49,234,000 | 444.39% | 1.26% |
| May 29, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | A | Common Stock | 125000 | $0.00 | 761,413.0000 | 49,234,000 | 19.64% | 0.25% |
| May 29, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | A | Common Stock | 14865 | $0.00 | 761,413.0000 | 49,234,000 | 1.99% | 0.03% |
| May 30, 2024 | Inhibrx Biosciences, Inc. | $INBX | Lappe Mark | Chief Executive Officer | A | Stock Option (right to buy) | 300000 | $0.00 | 300,000.0000 | 14,475,904 | 9999.99% | 2.07% |